Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer

Durvalumab + tremelimumab is active in mCRPC, but patient selection remains a challenge. Further studies to develop predictive biomarkers are warranted.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2024-11-08
DOI
https://doi.org/10.1158/1078-0432.ccr-24-1612
Citations
5
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
2.09

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer

Kim N. Chi, Daygen L. Finch, Francisco Vera-Badillo, Aaron R. Hansen et al.
5 citations
Clinical Cancer Research
Prostate Cancer Treatment and Research
2.09
article

Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer

Kim N. Chi, Daygen L. Finch, Francisco Vera-Badillo, Aaron R. Hansen, Aly‐Khan A. Lalani, Susan Ellard, Michael Ong, Eric Winquist, Lesley Seymour, Srikala S. Sridhar, James Hutchenreuther, Alexander W. Wyatt, Nayyer Iqbal, Sébastien J. Hotte, Michael Cabanero, Ming‐Sound Tsao, Martin Smoragiewicz, Christian Kollmannsberger, Urban Emmenegger, Elie Ritch, Muhammad Nur Salim, Stephen Yip, Joel Roger Gingerich, Christina Canil, Pierre Major
article en
5 citations

Abstract

Durvalumab + tremelimumab is active in mCRPC, but patient selection remains a challenge. Further studies to develop predictive biomarkers are warranted.

Clinical Cancer ResearchVol. 31(1)
Interior Health (CA), BC Cancer Agency (CA), Sunnybrook Health Science Centre (CA), University Health Network (CA), University of British Columbia (CA), Canadian Cancer Society (CA), University of Toronto (CA), Queen's University (CA), Juravinski Cancer Centre (CA), Ottawa Hospital (CA), London Health Sciences Centre (CA), Kelowna General Hospital (CA), Spinal Cord Injury BC (CA), Princess Margaret Cancer Centre (CA), Western Caspian University (AZ), CancerCare Manitoba (CA), Saskatchewan Cancer Agency (CA), Occupational Cancer Research Centre (CA), Canada's Michael Smith Genome Sciences Centre (CA), Canadian Centre for Applied Research in Cancer Control (CA), Kingston Health Sciences Centre (CA), Baker Hughes (Canada) (CA), Sunnybrook Hospital (CA), Ottawa Hospital Research Institute (CA), Sunnybrook Research Institute, University of Manitoba (CA), Hamilton Health Sciences (CA)
Canadian Cancer Society
Good health and well-being
Openalex Percentile: Top 12%
Prostate Cancer Treatment and Research
2.09
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.